Buck scientists restore long-term vision in blind mice, making a case for addressing the immune system’s role in rejecting transplanted cells
Stem cell therapies hold great promise for restoring function in a variety of degenerative conditions, but one of the logistical hurdles is how to ensure the cells survive in the body long enough to work. Researchers from the Buck Institute report one of the first demonstrations of long-term vision restoration in blind mice by transplanting photoreceptors derived from human stem cells and blocking the immune response that causes transplanted cells to be rejected by the recipient.
Publishing in the Cell Stem Cell, this work highlights immune system rejection as one of the key issues that needs to be addressed to improve efficiency of stem cell regeneration therapies. The findings support a path to improving clinical applications, specifically for restoring vision in humans by allowing photoreceptors derived from human stem cells to integrate and thrive in the eye.
“This turned into a nice story of long-term restoration of vision in completely blind mice,” said Buck faculty and senior author Deepak Lamba, PhD, MBBS. “We show that these mice can now perceive light as far out as 9-months following injection of these cells.”
Photoreceptors are specialized neurons in the retina that convert light into signals that the brain interprets as sight. Loss of these cells is a common endpoint in degenerative eye diseases. Human embryonic stem cells can provide a potential source for photoreceptor replacement, but despite Lamba’s prior work showing that photoreceptors derived from stem cells could function in mice, researchers hadn’t been able to show long-term sustained vision restoration. A major controversy in field, said Lamba, was whether the transplanted photoreceptors simply die off or were being actively rejected by the immune system – the eye, along with the brain, had long been thought to be “privileged” in that the cells of the immune system didn’t monitor those locations.
Lamba’s group set out to examine in detail the degree to which immune rejection contributes to disappointing outcomes in stem cell therapies for the eye, and to determine if they could find a way around the problem. If rejection was occurring and that could be suppressed, they reasoned, transplanted photoreceptors derived from stem cells might have time to integrate into the visual system and start relaying information to the brain.
The team used a specific mouse strain that is healthy but it is lacking in a specific immune cell receptor, which makes the mouse unable to reject transplanted foreign cells. Called immunodeficient IL2 receptor gamma (IL2r?) null mice, these animals lack the IL2r? receptor that humans also have as part of a functional immune system.
“This mouse strain is great model for this research because they are otherwise healthy and normal, including in their vision, so it allows us to conduct studies focused on cell integration,” said the publication’s lead author, Jie Zhu, PhD, a postdoctoral researcher who started in Lamba’s lab three years ago.
In these mice, the team showed that without the rejection process, there was a 10-fold increase of living human embryonic stem cell-derived donor retinal cells that matured and integrated into the retina.
After seeing significantly improved long-term survival and integration of the transplanted cells, the next step was to see if the cells actually functioned. The team transplanted stem cell-derived photoreceptors into another strain of mouse, called CRX null, which is congenitally blind. The team measured the pupils’ response to light and examined the brains’ visual response centers to show that signals from the eye were going to the appropriate areas of the brain. They found that even nine months to a year after photoreceptor transplantation, eyes were responding to light and transmitting sight messages to the brain.
“That finding gives us a lot of hope for patients, that we can create some sort of advantage for these stem cell therapies so it won’t be just a transient response when these cells are put in, but a sustained vision for a long time,” said Lamba. “Even though the retina is often considered to be ‘immune privileged,’ we have found that we can’t ignore cell rejection when trying to transplant stem cells into the eye.”
Dr. Lamba’s lab is dedicated to the clinical applications of human stem cells, with a special interest in restoring vision that has been compromised by degenerative eye diseases, such as macular degeneration. They are already refining the current work, said Zhu and Lamba. One direction is to use drugs already approved to prevent rejection for organ transplant that target the same IL2? receptor. “Using an antibody against this specific receptor means that the immune system might not need to be suppressed more generally, which can be very toxic,” said Zhu.
“We can also potentially identify other small molecules or recombinant proteins to reduce this interleukin 2 receptor gamma activity in the body – even eye-specific immune responses – that might reduce cell rejection,” said Lamba. “Of course it is not validated yet, but now that we have a target, that is the future of how we can apply this work to humans.”
Receive an email update when we add a new REGENERATIVE MEDICINE article.
The Latest on: Regenerative vision therapy
via Google News
The Latest on: Regenerative vision therapy
- WFIRM and Oracle Health Sciences collaborate on Body-on-a-Chip technologyon June 26, 2020 at 12:18 pm
WINSTON-SALEM, NC - June 25, 2020 - The Wake Forest Institute for Regenerative Medicine (WFIRM ... a one-size-fits all approach to medicine. The vision for the program is to use WFIRM's Body ...
- Valet Health & DataBiologics Combined Solution Support of Data-Driven Physicians Offering Orthobiologics Treatmentson June 26, 2020 at 6:05 am
Valet Health, a healthcare digital marketing company, is proud to announce a strategic partnership with DataBiologics, a robust data collection platform for tracking patient outcomes in orthobiologics ...
- California stem cell agency's $5.5 billion bond measure qualifies for the balloton June 24, 2020 at 10:47 am
A measure that would provide $5.5 billion for stem cell research has qualified for the Nov. 3 general election ballot. The initiative would rescue from financial extinction the California Institute ...
- Regenerative Medicine Market Size, Growth, Analysis and Share to surpass a USD 11.6 million valuation by 2028on June 22, 2020 at 6:49 am
Regenerative medicine is projected ... approval from the European Commission for luxturna, gene therapy to treat patients with a vision loss. The approval enhances the brand identity of the ...
- How people across the world still consuming some weird animal ingredients and still loving iton June 20, 2020 at 9:30 pm
Think snails crawling on your face, fish pedicure, bird poop facial, snake or snail massage, and leech and urine therapy ... for its hydrating potential and regeneration of skin, as it contains ...
- jCyte Inc. Enters into Ex-US Licensing and Commercialization Agreement for jCell Therapy with Global Ophthalmology Leader Santen Pharmaceuticalon June 18, 2020 at 5:00 pm
jCell therapy aims to preserve vision by intervening in the disease at a time when host photoreceptors can be protected and potentially reactivated. jCell has been developed with support from the ...
- Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen® for the Treatment of Dry AMD With Geographic Atrophyon June 18, 2020 at 6:14 am
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage cell therapy company which manufactures and transplants ...
- The good fighton June 18, 2020 at 2:38 am
My trust in the cosmic spirit who created me and my will to enjoy this beautiful world with mum where little birds still sing on the trees and there is still warm sunshine waiting for me, make me bold ...
- Lineage Cell Therapeutics to Host Therapeutic Expert Call Today to Discuss the First Known Reported Finding of Retinal Tissue Regeneration with OpRegen ® in Dry AMD with ...on June 8, 2020 at 5:31 am
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage cell therapy company which manufactures and transplants specific cell ...
via Bing News